Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Pamela Munster

Description

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Official Title

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

Keywords

Solid TumorTGF BetaPaclitaxelAlbumin-Bound PaclitaxelCisplatinGemcitabineLY3200882LY3300054nab-PaclitaxelIntensity Modulated RadiotherapyLY3200882 Schedule 1 EscalationLY3200882 Schedule 2 EscalationLY3200882 Schedule 1 ExpansionLY3200882 Schedule 2 ExpansionLY3200882 + Gemcitabine + nab-PaclitaxelLY3200882 + Cisplatin + Radiation

Eligibility

You can join if…

Open to people ages 18 years and up

  • The participant must have histological or cytological evidence of cancer.
  • Have adequate organ function.
  • Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
  • Are able to swallow capsules and tablets.

You CAN'T join if...

  • Have moderate or severe cardiovascular disease.
  • Have a serious concomitant systemic disorder.
  • Have acute leukemia.

Locations

  • University of California, San Franciscoaccepting new patients
    San FranciscoCalifornia94115United States
  • University of Texas MD Anderson Cancer Centeraccepting new patients
    HoustonTexas77030United States

Lead Scientist

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
more information about this study: A Study of LY3200882 in Participants With Solid Tumors
ID
NCT02937272
Phase
Phase 1
Study Type
Interventional
Last Updated